Circulate Health raised $12M in Seed Funding led by Khosla Ventures

In a significant move for the longevity industry, Circulate Health has secured $12 million in Seed funding. The round was led by the high-profile venture firm Khosla Ventures, with participation from Seaside Ventures and CSC Ventures. The company plans to use the new capital to expand its clinic network and accelerate development efforts for its core offering: using TPE to lower biological age and reduce the risk of age-related disease.

The Company & The Investors

• The longevity startup: Circulate Health is led by CEO Dr. Brad Younggren and co-founded by Dr. Eric Verdin of the Buck Institute. The company delivers a complete TPE solution: equipment, trained staff, and protocols; to longevity and wellness clinics

• Expertise: A cornerstone of Circulate’s development is the expertise of Dr. Dobri Kiprov, who serves as the company’s Chief Medical Officer. Widely recognized as one of the pioneers of therapeutic plasma exchange, Dr. Kiprov has spent decades advancing TPE as a safe, standardized medical procedure.

• The Lead Investor: The involvement of Khosla Ventures, a top-tier firm known for backing high-risk, high-reward "moonshot" companies, is a major endorsement of Circulate's novel business model.

• The Syndicate: The round is supported by Seaside Ventures, which focuses on health and wellness, and CSC Ventures, which brings expertise in scaling tech companies.

Therapeutic Plasma Exchange: The Technology

Therapeutic Plasma Exchange (TPE) is a procedure in which a patient’s blood is drawn, plasma is separated and discarded, and the blood cells are returned along with a replacement solution (such as albumin). Unlike “young blood” transfusions that primarily focus on adding rejuvenating factors, TPE’s primary action is removal: extracting pro-inflammatory proteins, autoantibodies, and other molecules that accumulate over time and contribute to age-related decline.

In many protocols, including Circulate’s published clinical study with the Buck Institute, TPE is followed by intravenous immunoglobulin (IVIG) infusion, which serves for replenishes protective antibodies that were lost in the “cleansing” process, and further modulates immune function.

The company’s data suggest that this combination can significantly impact biological aging. In their study, participants receiving TPE and IVIG experienced an average reduction of 2.6 years in measured biological age, with individuals who had higher burdens of inflammatory markers benefiting the most.

This emerging evidence positions TPE as a promising intervention for people who want to proactively address aging-related risks.

Why It Matters for Longevity

This investment signals a potential shift in ...